Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

508
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
508
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

1.4K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.4K
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

1.1K
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
1.1K
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

1.8K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.8K
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

533
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
533
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

1.1K
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

American Heart Association Guide for Improving Cardiovascular Health at the Community Level, 2013 update: a scientific statement for public health practitioners, healthcare providers, and health policy makers.

Circulation·2013
Same author

Ultrafiltration in heart failure with cardiorenal syndrome.

The New England journal of medicine·2013
Same author

Angiotensin-converting enzyme inhibitors and outcomes in heart failure and preserved ejection fraction.

The American journal of medicine·2013
Same author

Renin-Angiotensin system antagonists and mortality in patients with heart failure.

JAMA·2013
Same author

Digoxin reduces 30-day all-cause hospital admission in older patients with chronic systolic heart failure.

The American journal of medicine·2013
Same author

Lipid profile, lipid-lowering medications, and intracerebral hemorrhage after tPA in get with the guidelines-stroke.

Stroke·2013

Related Experiment Video

Updated: Mar 23, 2026

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

2.5K

New medications for heart failure.

Jonathan S Gordin1, Gregg C Fonarow2

  • 1Division of Cardiology, David Geffen School of Medicine at UCLA, Los Angeles, CA.

Trends in Cardiovascular Medicine
|April 4, 2016
PubMed
Summary

New heart failure medications, ivabradine and sacubitril/valsartan, improve outcomes. These therapies, alongside existing treatments, reduce heart failure hospitalizations and mortality.

Keywords:
Funny channelHeart failure therapiesIvabradineNeprilysinSacubitril/valsartan

More Related Videos

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

7.2K
Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

2.2K

Related Experiment Videos

Last Updated: Mar 23, 2026

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

2.5K
Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

7.2K
Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

2.2K

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Heart failure with reduced ejection fraction (HFrEF) significantly impacts morbidity and mortality.
  • Current guideline-based therapies target neurohormonal pathways, reducing HFrEF complications.
  • Further improvements in HFrEF outcomes are sought through novel pharmacological agents.

Purpose of the Study:

  • To review established guideline-directed medical therapies for HFrEF.
  • To discuss the translational research behind new HFrEF medications.
  • To present clinical trial results for ivabradine and sacubitril/valsartan in HFrEF.

Main Methods:

  • Review of established HFrEF therapies.
  • Analysis of translational research for novel drug development.
  • Summarization of major clinical trial data for ivabradine and sacubitril/valsartan.

Main Results:

  • Ivabradine reduces heart rate by targeting sinoatrial node If channels.
  • Sacubitril/valsartan combines neprilysin inhibition with angiotensin receptor antagonism.
  • Both agents, on background therapy, demonstrated improved clinical outcomes, including reduced hospitalizations and all-cause mortality.

Conclusions:

  • Ivabradine and sacubitril/valsartan represent significant advancements in HFrEF treatment.
  • These novel therapies offer improved outcomes when used with existing guideline-directed medical therapies.
  • Further research and clinical application of these agents are warranted for managing HFrEF.